Chris Evert's cancer returns, ruling her out of Wimbledon and reshaping a tennis summer

Chris Evert, one of the most decorated players in tennis history, said on 25 June 2026 that her ovarian cancer has returned and that treatment will keep her away from Wimbledon, the sport's marquee grass-court fortnight that begins on 29 June 2026. The 71-year-old's announcement, made on a day when tennis broadcasters and former champions typically gather at the All England Club for the Champions' Dinner and the early rounds of qualifying, lands as Wimbledon prepares to crown a new women's champion and as ESPN, the tournament's American rightsholder, finalises its on-air roster for the two-week broadcast.

The recurrence is the second time Evert has confronted the disease publicly. In January 2022 she revealed a stage 1C ovarian cancer diagnosis; a year later, in May 2023, she said a subsequent scan had found no evidence of further disease. The newest disclosure, reported by ESPN on 25 June 2026, returns her to active treatment and removes, for now, one of the most recognisable voices in American tennis commentary from the chair at the All England Club.

A broadcast chair sits empty

Evert has been a central figure in ESPN's tennis coverage for the better part of three decades, joining the network as a lead analyst in the 1990s and remaining a fixture at the Australian Open, the French Open, Wimbledon and the US Open. Her absence from the Wimbledon booth is a programming change as much as a personal one: ESPN's Wimbledon primetime coverage, which it markets heavily to American audiences, is built around a small roster of marquee analysts, and Evert's name has long anchored that pitch.

The network has not, as of 25 June 2026, publicly named her replacement for the 2026 Championships. Industry expectations are that a former player of comparable stature — Mary Joe Fernandez, Pam Shriver, or a returning Tracey Austin are the names most often mentioned in tennis press coverage — will fill the role on a tournament-by-tournament basis. The gap is also a logistical one: Wimbledon runs back-to-back men's and women's semifinals on the second Thursday and the men's and women's finals on the second Sunday, a 14-day sprint that tests any analyst roster.

The personal cost of a public diagnosis

Evert's 2022 disclosure came in a first-person essay and was followed by six rounds of chemotherapy. Her 2023 update, again published in essay form, was widely cited by cancer-advocacy groups as a model of responsible public disclosure — specific, calm, and explicit about the follow-up scans that caught the original disease at an early stage. The 2026 return of the disease, by contrast, is the harder version of the story: a recurrence after a period of remission that advocacy groups describe as a particular kind of blow to patients and their families.

Ovarian cancer carries a documented risk of recurrence even after successful initial treatment, with survival statistics tracked by cancer registries in the United States and the United Kingdom. The Tennis Channel, NBC and the major wire services have, in past coverage of Evert's diagnosis, pointed to those registries as context for the long arc of the disease. Evert herself has not, in her 2026 statement, specified a treatment plan or a timeline; the ESPN report on 25 June 2026 said only that "treatment will prevent her from attending Wimbledon this year," leaving the medical detail to her and her physicians.

What remains uncertain

The short public record of 25 June 2026 is thin on the medical specifics that patients, oncologists and advocacy organisations typically want. The ESPN report does not name a treating institution, does not specify a stage, and does not say whether the recurrence was detected by routine surveillance imaging, by a symptom-driven workup, or both. It also does not project a return to broadcasting or to public life.

The structural frame, such as it is, sits inside a long-running debate about how cancer recurrences are reported in public figures. American sports media has covered the arcs of athletes with cancer — most prominently the careers of Arthur Ashe, who disclosed an AIDS diagnosis in 1992, and Martina Navratilova, who announced a breast cancer diagnosis in 2010 and a recurrence-free status in 2014 — with a mix of medical detail and deference to the patient's own timeline. Evert's 2026 disclosure fits that pattern: a single statement, an immediate pivot to treatment, and an implicit request for privacy on the medical specifics. What is not yet known — the stage, the regimen, the projected recovery window — is also what most matters to readers tracking the story for reasons of their own.

The Wimbledon draw ceremony takes place on 26 June 2026, the day after Evert's disclosure. The women's bracket is expected to be led by the reigning Australian Open and Roland Garros champions; the men's by the Paris finalist and the reigning Wimbledon titlist. ESPN's coverage, with or without Evert in the booth, will run from the opening Monday through the second Sunday. The tournament will go on, as it always does, and the chair that Evert occupied for the better part of three decades will, in 2026, be filled by someone else.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://en.wikipedia.org/wiki/Chris_Evert
• https://en.wikipedia.org/wiki/2026_Wimbledon_Championships
• https://en.wikipedia.org/wiki/Ovarian_cancer